Essential Thrombocythemia (ET) Cell Models for Research

Essential Thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by sustained thrombocytosis and an increased risk of thrombosis and hemorrhage. According to the World Health Organization (WHO) classification (2016), ET is a BCR-ABL1-negative MPN. The annual incidence is estimated at 1.5 to 2.5 per 100,000 population, with a median age at diagnosis of 60 years, though it can occur in younger adults. The 5-year overall survival for ET is approximately 80-90%, but survival is reduced in patients with high-risk features such as age >60 years, leukocytosis, and thrombosis history. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database does not track ET separately, but MPNs collectively have a 5-year survival of about 70%. Key risk factors include age, prior thrombosis, and cardiovascular risk factors. ET is a clonal disorder of hematopoietic stem cells, leading to overproduction of platelets. Research is crucial to understand the molecular drivers and to develop targeted therapies that reduce thrombotic risk without increasing bleeding.

ET is an ideal model for studying myeloproliferative disorders because it is driven by well-defined somatic mutations in a limited set of genes (JAK2, CALR, MPL), making it amenable to genetic modeling. The disease has a long preclinical phase, providing a window for intervention studies. Public datasets, such as those from the International Cancer Genome Consortium (ICGC) and the Catalogue of Somatic Mutations in Cancer (COSMIC), provide extensive genomic data. Open questions include the mechanisms of disease progression to myelofibrosis or acute leukemia, the role of additional somatic mutations, and the development of targeted therapies that selectively inhibit mutant clones. Gene-edited cell models are essential for functional validation of these mutations and for drug screening.

The pathogenesis of ET is driven by constitutive activation of the JAK-STAT signaling pathway, leading to uncontrolled megakaryopoiesis and platelet production. The major pathways include:

1. JAK2-STAT pathway: Mutations in JAK2 (e.g., V617F) result in constitutive kinase activity, leading to phosphorylation of STAT5 and downstream activation of genes involved in cell proliferation and survival.

2. CALR pathway: Mutant calreticulin (CALR) binds to the thrombopoietin receptor (MPL) and activates JAK2 in a ligand-independent manner, promoting megakaryocyte differentiation.

3. MPL pathway: Mutations in MPL (e.g., W515L) cause constitutive activation of the thrombopoietin receptor, leading to JAK2 activation.

4. PI3K/AKT and MAPK pathways: These are downstream effectors of JAK-STAT signaling and contribute to cell survival and proliferation.

These pathways converge on the transcription factor STAT5, which upregulates genes like BCL2L1 (anti-apoptotic) and CCND1 (cell cycle).

Data from COSMIC and TCGA (PanCancer) studies. Frequencies vary by cohort.

Key signaling networks deregulated in ET include:

• • JAK-STAT pathway: Central to ET pathogenesis. Mutations in JAK2, CALR, and MPL lead to constitutive STAT5 activation.
• • PI3K/AKT/mTOR pathway: Activated downstream of JAK2, promoting cell survival and protein synthesis.
• • MAPK/ERK pathway: Contributes to megakaryocyte proliferation and differentiation.
• • NF-κB pathway: Involved in inflammatory cytokine production and resistance to apoptosis.
• • Epigenetic regulators: TET2 and ASXL1 mutations affect DNA methylation and chromatin structure, contributing to clonal evolution.

Key nodes: STAT5, JAK2, MPL, CALR, PI3K, AKT, ERK, NF-κB.

Organoids: 3D bone marrow organoids can recapitulate the hematopoietic niche and are useful for studying megakaryopoiesis and drug response. They are generated from patient-derived CD34+ cells and can be genetically modified using CRISPR.

Animal models for ET include:

• • Patient-derived xenografts (PDX): Immunodeficient mice (e.g., NSG) are transplanted with patient CD34+ cells, allowing in vivo study of human ET cells.
• • Genetically engineered mouse models (GEMM): Knock-in of JAK2 V617F or CALR mutations in hematopoietic stem cells using Cre-lox or CRISPR, leading to ET-like phenotype.
• • Induced models: Use of viral vectors to express mutant JAK2 or CALR in mouse bone marrow, followed by transplantation.

These models are used to study disease progression, test targeted therapies, and evaluate the role of cooperating mutations.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific mutations found in ET. For example:

• • JAK2 V617F knock-in: Introduction of the V617F mutation into a JAK2 wild-type cell line (e.g., K562) to study the gain-of-function effect.
• • CALR frameshift knock-in: Mimicking type 1 or type 2 CALR mutations to study MPL activation.
• • MPL W515L knock-in: Constitutive activation of MPL.
• • TET2 knockout: Loss-of-function to study epigenetic dysregulation.

These models are commercially available from various sources, and are sequence-verified and validated for functional readouts. They accelerate research by providing consistent, reproducible models for drug screening and mechanistic studies. Isogenic pairs (wild-type vs. mutant) are particularly valuable for target validation.

Gene-edited cell lines are used to validate the functional role of ET-associated mutations. For example:

• • JAK2 V617F knock-in in K562 cells leads to constitutive STAT5 phosphorylation and increased proliferation, confirming the oncogenic role.
• • CALR knockout in HEL cells reduces MPL activation and downstream signaling, demonstrating the dependence of mutant CALR on MPL.
• • TET2 knockout in SET2 cells alters DNA methylation and gene expression, linking TET2 to clonal hematopoiesis.

These models allow for loss-of-function and gain-of-function studies in a controlled genetic background.

Isogenic cell line pairs (wild-type vs. mutant) are used for high-throughput drug screening. For example:

• • Screening JAK2 inhibitors (e.g., ruxolitinib) on JAK2 V617F knock-in vs. wild-type cells to assess selectivity.
• • Resistance modeling: Chronic exposure of mutant cells to inhibitors can select for resistant clones, revealing secondary mutations or compensatory pathways.
• • Combination screening: Using gene-edited cells to test synergistic effects of JAK2 inhibitors with other agents (e.g., PI3K inhibitors).

CRISPR-based synthetic lethality screens can identify novel therapeutic targets. For example:

• • In JAK2 V617F cells, a CRISPR knockout screen can identify genes that are essential only in the mutant context, such as components of the JAK-STAT pathway or downstream effectors.
• • Biomarker discovery: Gene-edited cells can be used to identify secreted proteins or surface markers that correlate with disease state, aiding in diagnosis or monitoring.
• • Example: Knockout of PIM1 kinase in JAK2 mutant cells reduces cell viability, suggesting PIM1 as a potential biomarker and target.